Digestion (Large Intestine)
The colon health focus of the Company is currently focused towards the use of high and low molecular weight carbohydrates (e.g. mannans) to: Provide fibre; Promote a healthy gut microflora; Encapsulate and remove pathogens from the gut; Provide therapeutic options for gut specific diseases (such as IBD); Promote topical healing within the gut; Provide systemic therapeutic opportunities (e.g. skin) via for example the GALT system. The structure, bioactivity and physiological properties of mannans, for example, make them advantageous with respect to healthcare compared to some other sources of carbohydrates. Animal and human faecal trials are complete where prebiotic-type efficacy and overall gut health has been proven. At this time, trials are focussed on (IBD) and blood lipid (especially cholesterol) absorption regulation from the gut. Other gut related health/disorder applications are also being developed.
Formulation/sensory trials to begin with partners in 2018.